Skip to Main Content

Author Details

Massimo Cristofanilli
Weill Cornell School of Medicine
1998
420
88
Emma Lundberg (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37548439Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.Oncologist2024
36892508Prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor from a real-world database analysis: a plain language summary.Future Oncol2023
37090580Computational ranking-assisted identification of Plexin-B2 in homotypic and heterotypic clustering of circulating tumor cells in breast cancer metastasis.bioRxiv2023
36989609Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer.J Clin Oncol2023
37345070ICAM-1-suPAR-CD11b Axis Is a Novel Therapeutic Target for Metastatic Triple-Negative Breast Cancer.Cancers (Basel)2023
37141549Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.JCO Precis Oncol2023
37437342The immunogram of inflammatory breast cancer.Cancer Treat Rev2023
37437229Circulating Tumor DNA and Unique Actionable Genomic Alterations in the Longitudinal Monitoring of Metastatic Breast Cancer: A Case of <i>FGFR2-KIAA1598</i> Gene Fusion.JCO Precis Oncol2023
37272843Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer.Cancer Discov2023
37070653Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.Future Oncol2023
37265453Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.Clin Cancer Res2023
36993871Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date.Onco Targets Ther2023
36621430A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases.Clin Breast Cancer2023
36608132Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity.Sci Adv2023
36672285Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide.Cancers (Basel)2023
34780297Standard of Care in Hormone Receptor-Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools?JCO Oncol Pract2022
35806301Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer.Int J Mol Sci2022
35740538Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism.Cancers (Basel)2022
35772051Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.JCO Precis Oncol2022
35606863CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome.Breast Cancer Res2022
35468539Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives.Cancer Treat Rev2022
35552673Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.Clin Cancer Res2022
36139501MARCKS as a Potential Therapeutic Target in Inflammatory Breast Cancer.Cells2022
36332363Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.EBioMedicine2022
36358657A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix<sup>®</sup> PC1 System.Cancers (Basel)2022
35954396CDC20-Mediated hnRNPU Ubiquitination Regulates Chromatin Condensation and Anti-Cancer Drug Response.Cancers (Basel)2022
36193887Machine learning-assisted elucidation of CD81-CD44 interactions in promoting cancer stemness and extracellular vesicle integrity.Elife2022
36220852Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.NPJ Breast Cancer2022
35974168Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib.NPJ Precis Oncol2022
35042871Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.NPJ Breast Cancer2022
35126865Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers.Oncotarget2022
35278078Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.Oncologist2022
35273384Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'?Br J Cancer2022
35265204Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior.Theranostics2022
35078818Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.Cancer Res2022
35048267Leptomeningeal metastases: the future is now.J Neurooncol2022
34525344Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.Cell Chem Biol2022
32940689Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.J Natl Cancer Inst2021
33486783Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5â¿¿Years of Follow-Up.Oncologist2021
33761995Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.Breast Cancer Res2021
33649493Surfactant-assisted one-pot sample preparation for label-free single-cell proteomics.Commun Biol2021
33893888New Treatment Strategies for the Inflammatory Breast Cancer.Curr Treat Options Oncol2021
33529077Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology.JCO Glob Oncol2021
35008244Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer.Cancers (Basel)2021
34471951Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China.Breast Cancer Res Treat2021
34381029ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer.Nat Commun2021
34570988Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer.Expert Rev Mol Diagn2021
34534657Understanding metastasis in breast cancer to improve detection, monitoring and treatment.Crit Rev Oncol Hematol2021
34445631Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC).Int J Mol Sci2021
33995681EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer.Theranostics2021
  • 1 - 50 of 420

Recommended Authors

Kevin Punie
Leuven Cancer Institute and University Hospitals Leuven
Career Start Year 2015
Number of shared co-authors 12
Martin Sj??str??m
University of California-San Francisco
Career Start Year 2013
Number of shared co-authors 1
Konstantinos Tryfonidis
Merck & Co., Inc.
Career Start Year 2011
Number of shared co-authors 6
Yin Liu
Fudan University Shanghai Cancer Center
Career Start Year 2011
Number of shared co-authors 0
Theodora Goulioti
Career Start Year 2009
Number of shared co-authors 6
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 6
Sharon F McGee
The Ottawa Hospital Cancer Centre
Career Start Year 2006
Number of shared co-authors 2
Naoto Kondo
Nagoya City University Graduate School of Medical Sciences
Career Start Year 2006
Number of shared co-authors 1
Catherine M Kelly
Mater Misericordiae University Hospital
Career Start Year 2006
Number of shared co-authors 11
Christina Yau
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 11
Carolien H M van Deurzen
Erasmus MC Cancer Institute
Career Start Year 2004
Number of shared co-authors 8
Jeong Eon Lee
Samsung Medical Center, Sungkyunkwan University School of Medicine
Career Start Year 2004
Number of shared co-authors 0
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 6
Joshua Chuck Harrell
Virginia Commonwealth University
Career Start Year 2002
Number of shared co-authors 0
Peter A Fasching
Otto-Friedrich-University Bamberg
Career Start Year 2002
Number of shared co-authors 13
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 16
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Career Start Year 2000
Number of shared co-authors 24
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 8
Steven J Isakoff
Massachusetts General Hospital
Career Start Year 1995
Number of shared co-authors 13
Carolien P Schr??der
University of Groningen, University Medical Center Groningen
Career Start Year 1995
Number of shared co-authors 5
Barbro Linderholm
Sahlgrenska University Hospital
Career Start Year 1994
Number of shared co-authors 10
Susan J Done
University Health Network
Career Start Year 1994
Number of shared co-authors 0
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 5
John M S Bartlett
University of Edinburgh
Career Start Year 1992
Number of shared co-authors 11
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 11
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 11
Laura J Van't Veer
University of California San Francisco
Career Start Year 1984
Number of shared co-authors 21
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 2
Hans-Peter Sinn
Pathologisches Institut, Universitatsklinikum Heidelberg
Career Start Year 1981
Number of shared co-authors 3
James N Ingle
Mayo Clinic
Career Start Year 1952
Number of shared co-authors 12

Collaborators

Gabriel N Hortobagyi
The University of Texas MD Anderson Cancer Center
Co-authored papers 96
James M Reuben
The University of Texas MD Anderson Cancer Center
Co-authored papers 60
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Co-authored papers 53
Thomas A Buchholz
Co-authored papers 34
Lajos Pusztai
Co-authored papers 25
Zhaomei Mu
Thomas Jefferson University Hospital
Co-authored papers 20
Fredika M Robertson
University of Texas M.D. Anderson Cancer Center
Co-authored papers 18
William F Symmans
Co-authored papers 16
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Co-authored papers 14
Kelly K Hunt
The University of Texas MD Anderson Cancer Center
Co-authored papers 13
Eleni Andreopoulou
New York Presbyterian Hospital
Co-authored papers 12
Firas H Wehbe
Feinberg School of Medicine, Northwestern University
Co-authored papers 10
Giuseppe Curigliano
University of Milan
Co-authored papers 10
Juan P Palazzo
Thomas Jefferson University Hospital
Co-authored papers 9
Luc Dirix
GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp
Co-authored papers 8
Bingshan Li
Co-authored papers 8
Kenneth R Hess
The University of Texas MD Anderson Cancer Center
Co-authored papers 8
Aditya Bardia
Massachusetts General Hospital Cancer Center
Co-authored papers 7
Huiping Liu
Co-authored papers 7
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Co-authored papers 7
Rebecca Nagy
Guardant Health Inc.
Co-authored papers 6
Jeffrey S Ross
Foundation Medicine
Co-authored papers 6
Yuzhi Jia
Feinberg School of Medicine, Northwestern University
Co-authored papers 6
Daniel Birnbaum
Co-authored papers 5
Vincent A Miller
Injury Prevention Research Center, University of North Carolina
Co-authored papers 5
Siraj M Ali
Foundation Medicine
Co-authored papers 4
Mien-Chie Hung
Co-authored papers 4
Cynthia X Ma
Co-authored papers 4
Matthew J Ellis
Co-authored papers 4
Lifang Hou
Co-authored papers 4
Release 1.2